Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Anna Maria Di Giacomo(University of Siena), Michele Maio(University of Siena), Alessia Covre(University of Siena), Luana Calabrò(University of Siena), Mario Mandalà(University of Perugia), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Giovanni Amato(Institute for Experimental Endocrinology and Oncology), Ornella Cutaia(University of Siena), Michele Guida(Istituto Tumori Bari), Pietro Quaglino(Department of Medical Sciences), Monica Valente(University of Siena), Diana Giannarelli(Agostino Gemelli University Polyclinic), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Roberto Camerini(Associazione Italiana Vulvodinia Onlus)
Cited by 75
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k